IDH1 mutations generate a gain-of-function conversion of α-ketoglutarate (αKG) to D-2-hydroxyglutarate (D2HG) that in turn inhibits DNA histone demethylases, resulting in hypermethylation-associated epigenetic tumor cell reprogramming1. This evidence concerns the gene IDH1 and neoplasm.